Label Changes for:
Parnate (tranylcypromine sulfate) tablets
Changes have been made to the CONTRAINDICATIONS sections of the safety label.
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – May 2010 and November 2009
In combination with sympathomimetics
- Parnate should not be administered in combination with sympathomimetics, including amphetamines which may be found in many herbal preparations
- Cerebral hemorrhage may also occur
- Parnate is contraindicated: In combination with selective norepinephrine reuptake inhibitors (SNRIs)